Clinical Trial Detail

NCT ID NCT03679767
Title A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

renal cell carcinoma

lung non-small cell carcinoma

transitional cell carcinoma

melanoma

Therapies

Retifanlimab

Age Groups: adult senior

Additional content available in CKB BOOST